A Phase III Randomized Open-Label Study of Acalabrutinib and Venetoclax Versus Venetoclax and Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Trial ID
- 2023-505866-27-00
- Protocol
- D8220C00027
- Sponsor
- AstraZeneca AB
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this Phase III trial is to evaluate whether minimal residual disease (MRD)-driven finite treatment with **acalabrutinib** plus **venetoclax** (AV) is non-inferior to MRD-driven finite treatment with **venetoclax** plus **obinutuzumab** (VO) in terms of progression-free survival (PFS) in patients with previously untreated **Chronic Lymphocytic Leukemia** or **Small Lymphocytic Lymphoma**. This is clinically relevant as it may offer an alternative treatment regimen with potentially similar efficacy in delaying disease progression.
Secondary objectives include:
- Assessing the effect of AV treatment compared with VO treatment on undetectable minimal residual disease (uMRD) at sequential timepoints.
- Evaluating the impact on overall survival (OS).
- Determining the effect on event-free survival (EFS).
- Comparing the overall response rate (ORR) between the two treatment regimens.
- Assessing symptoms, functional status, global health status/quality of life (QoL), and patient perceived benefit-risk using the EORTC QLQ-C30, EORTC QLQ-CLL17, NCI PRO-CTCAE item for bruising, and PGI-BR.
Participants
The clinical trial involves a total of **371 participants** diagnosed with **Chronic Lymphocytic Leukemia** or **Small Lymphocytic Lymphoma**. The study population includes both male and female subjects, aged 18 years and older, with documented treatment-naïve CLL/SLL requiring treatment as per iwCLL guidelines 2018. Participants were selected based on their ability to meet specific laboratory parameters and adequate bone marrow function, independent of growth factor or platelet transfusion support. The trial includes individuals with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, indicating a stable health status without significant deterioration in the two weeks prior to baseline or the day of first dosing. The study population also considers vulnerable groups, ensuring a comprehensive assessment of the treatment's efficacy and safety across diverse demographics. Lifestyle factors such as diet and physical activity are not specified in the available data.
Plans and Procedures
The clinical trial is a Phase III, prospective, multicenter, randomized, open-label study designed to evaluate the efficacy of **acalabrutinib** plus **venetoclax** versus **venetoclax** plus **obinutuzumab** in patients with previously untreated **Chronic Lymphocytic Leukemia** (CLL) or **Small Lymphocytic Lymphoma** (SLL). The primary objective is to assess whether minimal residual disease (MRD)-driven finite treatment with acalabrutinib and venetoclax is non-inferior to MRD-driven finite treatment with venetoclax and obinutuzumab in terms of progression-free survival (PFS). The trial is expected to conclude by May 31, 2029, with recruitment having commenced on May 31, 2022.
The trial involves a series of structured visits, beginning with a screening visit to confirm eligibility based on criteria such as age, documented need for treatment, and adequate bone marrow function. Participants must be 18 years or older and meet specific laboratory parameters. Following randomization, participants will undergo regular follow-up visits to monitor treatment response and safety. The end-of-study visit will assess the primary and secondary endpoints, including PFS, overall survival, and the rate of undetectable MRD in peripheral blood.
Participants are expected to be involved in the study for a maximum treatment period of 96 weeks, depending on the treatment arm. Conditions that may lead to early termination from the study include disease progression, unacceptable toxicity, or withdrawal of consent. The study employs a randomized, open-label design, allowing for direct comparison of the two treatment regimens. The trial's endpoints will be evaluated based on investigator assessments and standardized criteria, ensuring robust and reliable data collection.
Treatment
The clinical trial involves the administration of several experimental medications, each with specific pharmaceutical forms, dosages, and administration routes. **Venetoclax** is provided in three different strengths: 10 mg, 50 mg, and 100 mg film-coated tablets. The maximum daily dose for **Venetoclax** is 400 mg, with a total maximum dose of 251.79 g over a treatment period of up to 96 weeks. The tablets are administered orally. **Venetoclax** is a chemical substance, and its role in the trial is as a comparator treatment.
**Acalabrutinib** is available in two forms: 100 mg film-coated tablets and 100 mg hard capsules. The maximum daily dose for **Acalabrutinib** is 200 mg, with a total maximum dose of 134.4 g over a treatment period of up to 96 weeks. Both the tablets and capsules are administered orally. **Acalabrutinib** is also a chemical substance and serves as a test treatment in the trial. The clinical supply of **Acalabrutinib** differs from the marketed product, as it is provided in HDPE bottles and may use printed or unprinted capsules.
**Obinutuzumab** is provided as a 1,000 mg concentrate for solution for infusion. The maximum daily dose is 1,000 mg, with a total maximum dose of 8,000 mg over a treatment period of up to 24 weeks. The administration route for **Obinutuzumab** is intravenous. It is a protein-based substance and is designated as an orphan drug in this trial, serving as a comparator treatment.
Participant compliance with the dosing schedule is monitored throughout the trial. The trial aims to assess the efficacy of **Acalabrutinib** plus **Venetoclax** versus **Venetoclax** plus **Obinutuzumab** in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study is designed to evaluate the progression-free survival (PFS) of the treatments based on minimal residual disease (MRD) status.
Efficacy
The efficacy of the clinical trial will be assessed using several primary and secondary endpoints. The primary endpoint is **Progression-Free Survival (PFS)**, defined as the time from the date of randomization until the date of objective progressive disease per iwCLL 2018 criteria, as assessed by the investigator, or death from any cause in the absence of progression. Secondary endpoints include the rate of peripheral blood undetectable minimal residual disease (uMRD), overall survival, event-free survival, overall response rate, complete response (CR) rate after completion of 12 cycles of venetoclax, and changes from baseline in EORTC QLQ-C30 and EORTC QLQ-CLL17 scales. Additionally, the proportion of participants experiencing bruising and the proportion of participants reporting each response option of the Patient Global Impression of Bruising (PGI-BR) will be evaluated.
The trial is a Phase III, prospective, multicenter, randomized, open-label study comparing Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in previously untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The efficacy parameters will be measured and collected at various timepoints throughout the trial, with specific methods and tools such as validated scales and laboratory tests being employed to ensure accurate and reliable data collection. The analysis of these parameters will be conducted in accordance with the trial protocol to determine the efficacy of the treatment regimens under investigation.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Participant must be ≥ 18 years at the time of signing the consent form
- Documented TN CLL/SLL requiring treatment according to iwCLL guidelines 2018 (Hallek et al 2018) including a detectable clonal B-cell population at baseline for purposes of measuring for MRD
- Adequate BM function independent of growth factor or platelet transfusion support within 2 weeks of screening initiation as follows: (a) Absolute neutrophil count ≥ 1.0 × 10^9/L; absolute neutrophil count ≥ 500 cells/μL (≥ 0.50 × 10^9/L) with documented BM involvement of CLL/SLL (b) Platelet counts ≥ 30 × 10^9/L; platelet count ≥ 10 × 10^9/L in participants with documented BM involvement of CLL/SLL
- Estimated CrCL of ≥ 30 mL/min, calculated by Cockcroft-Gault (using actual body weight), or serum creatinine < 2 × ULN: Males: CrCL (mL/min) = Weight (kg) × (140 - Age) / 72 × serum creatinine (mg/dL) Females: CrCL (mL/min) = Weight (kg) × (140 - Age) × 0.85 / 72 × serum creatinine (mg/dL)
- Meet the following laboratory parameters (ULN is based on institutional standards): (a) Serum AST and ALT ≤ 3 × ULN (Higher thresholds may be allowed if hepatic dysfunction is attributable to CLL/SLL and after discussion with the Sponsor Hematology Safety Knowledge Group). (b) Total bilirubin ≤ 1.5 × ULN, unless directly attributable to Gilbert's syndrome
- An ECOG performance status of 0 to 2 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing
Exclusion Criteria
- As judged by the investigator, any evidence of past or current diseases that, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize their safety or compliance with the protocol or would put the study at risk
- Clinically significant cardiovascular disease, such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction, within 6 months of screening or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
- Active bleeding or history of bleeding diathesis (eg, hemophilia or von Willebrand disease)
- Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura
- History of significant cerebrovascular disease/event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study intervention
- Child-Pugh B/C liver cirrhosis
- History of prior or current malignancy (including but not limited to known central nervous system involvement such as by CLL/SLL, leptomeningeal disease, or spinal cord compression, known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome) that could affect compliance with the protocol or interpretation of results. Possible examples where compliance or data interpretation may not be affected could include the following, per physician discretion. (a) Curatively treated BCC or SCC of the skin or carcinoma in situ of the cervix or carcinoma in situ of the prostate at any time prior to study. (b) Other cancers that have been curatively treated from which the participant is disease-free for ≥ 3 years without further treatment
- Any prior CLL/SLL-specific therapies, except prior rituximab if used for autoimmune cytopenias and not as anti-CLL/SLL treatment
- Corticosteroid use > 20 mg within 1 week before the first dose of study intervention, except as indicated for other medical conditions, such as autoimmune cytopenias, inhaled steroid for asthma, topical steroid use, or as premedication for administration of study intervention or contrast
- Requires treatment with a strong cytochrome CYP3A4 inhibitor/inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited
- Concurrent participation in another therapeutic clinical trial. Use of investigational agents that interfere with the study intervention(s) within 30 days or 5 half-lives (whichever is longer) prior to registration for study screening
- Prothrombin time/INR or activated partial thromboplastin time, in the absence of lupus anticoagulant or attributed to anticoagulant (eg, direct oral anticoagulant) > 2 × ULN
- Currently pregnant (confirmed with positive pregnancy test) or breast feeding
- WOCBP unless the following criteria are met: a negative pregnancy test at least 30 days before start of study intervention, followed by immediate highly effective contraception; further pregnancy testing will be performed every cycle and as clinically indicated.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Czechia | Not Recruiting | 31 May 2022 | 100 |
France | Not Recruiting | 31 May 2022 | 67 |
Hungary | Not Recruiting | 31 May 2022 | 51 |
Poland | Not Recruiting | 31 May 2022 | 142 |
Spain | Not Recruiting | 31 May 2022 | 27 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Gazyvaro 1,000 mg concentrate for solution for infusion. | Comparator | CONCENTRATE FOR SOLUTION FOR INFUSION | INTRAVENOUS USE | 1000 | 24 | PRD1753415 |
Venclyxto 10 mg film-coated tablets | Comparator | FILM-COATED TABLETS | ORAL USE | 400 | 96 | PRD6353822 |
Venclyxto 100 mg film-coated tablets | Comparator | FILM-COATED TABLETS | ORAL USE | 400 | 96 | PRD6353834 |
Venclyxto 50 mg film-coated tablets | Comparator | FILM-COATED TABLETS | ORAL USE | 400 | 96 | PRD6353830 |
Calquence 100 mg film-coated tablets | Test | FILM-COATED TABLETS | ORAL USE | 200 | 96 | PRD10242587 |
Venclyxto 100 mg film-coated tablets | Comparator | FILM-COATED TABLETS | ORAL USE | 400 | 96 | PRD6353842 |
Calquence 100 mg film-coated tablets | Test | FILM-COATED TABLETS | ORAL USE | 200 | 96 | PRD10242588 |
Venclyxto 100 mg film-coated tablets | Comparator | FILM-COATED TABLETS | ORAL USE | 400 | 96 | PRD6353838 |
Venclyxto 50 mg film-coated tablets | Comparator | FILM-COATED TABLETS | ORAL USE | 400 | 96 | PRD6353826 |
Calquence 100 mg hard capsules | Test | HARD CAPSULES | ORAL USE | 200 | 96 | PRD8485701 |





